Runbo Zhong

1.6k total citations · 1 hit paper
89 papers, 1.1k citations indexed

About

Runbo Zhong is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Runbo Zhong has authored 89 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Runbo Zhong's work include Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Research Studies (33 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Runbo Zhong is often cited by papers focused on Lung Cancer Treatments and Mutations (41 papers), Lung Cancer Research Studies (33 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Runbo Zhong collaborates with scholars based in China, United States and Italy. Runbo Zhong's co-authors include Baohui Han, Hua Zhong, Jiajun Teng, Jianlin Xu, Tianqing Chu, Hua Zhong, Hua Zhong, Yanwei Zhang, Jun Lü and Xueyan Zhang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Runbo Zhong

85 papers receiving 1.1k citations

Hit Papers

Phase 1b Study of Sintilimab Plus Anlotinib as First-line... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
    2021 174 citations Tianqing Chu, Runbo Zhong et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Runbo Zhong China 18 715 440 275 248 171 89 1.1k
Hari Menon United States 17 661 0.9× 398 0.9× 321 1.2× 330 1.3× 227 1.3× 46 1.2k
Chuanyong Mu China 12 761 1.1× 352 0.8× 155 0.6× 375 1.5× 114 0.7× 24 964
Simon Laban Germany 22 666 0.9× 272 0.6× 500 1.8× 351 1.4× 262 1.5× 127 1.3k
Alexandra S. Zimmer United States 13 815 1.1× 344 0.8× 365 1.3× 192 0.8× 110 0.6× 24 1.1k
Margaret E. Gatti‐Mays United States 16 746 1.0× 170 0.4× 306 1.1× 539 2.2× 137 0.8× 74 1.1k
Max M. Wattenberg United States 14 843 1.2× 251 0.6× 240 0.9× 505 2.0× 250 1.5× 25 1.2k
Gabriele Gamerith Austria 18 507 0.7× 200 0.5× 233 0.8× 178 0.7× 193 1.1× 44 914
An Coosemans Belgium 21 523 0.7× 283 0.6× 409 1.5× 545 2.2× 238 1.4× 76 1.6k
Shuhua Wei China 12 443 0.6× 195 0.4× 347 1.3× 559 2.3× 157 0.9× 21 1.1k
Carlos de Andrea Spain 10 658 0.9× 234 0.5× 231 0.8× 519 2.1× 142 0.8× 23 1.1k

Countries citing papers authored by Runbo Zhong

Since Specialization
Citations

This map shows the geographic impact of Runbo Zhong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Runbo Zhong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Runbo Zhong more than expected).

Fields of papers citing papers by Runbo Zhong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Runbo Zhong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Runbo Zhong. The network helps show where Runbo Zhong may publish in the future.

Co-authorship network of co-authors of Runbo Zhong

This figure shows the co-authorship network connecting the top 25 collaborators of Runbo Zhong. A scholar is included among the top collaborators of Runbo Zhong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Runbo Zhong. Runbo Zhong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Qiang, Huiping, Yao Zhang, Jingwen Li, et al.. (2025). Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer. Translational Oncology. 53. 102317–102317. 4 indexed citations
2.
Zhang, Huihui, Runbo Zhong, Wanting Wang, et al.. (2025). OX40–heparan sulfate binding facilitates CAR T cell penetration into solid tumors in mice. Science Translational Medicine. 17(803). eadr2151–eadr2151. 4 indexed citations
3.
Zhong, Hua, et al.. (2025). Comparison of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib in untreated advanced EGFR-mutated NSCLC. Annals of Medicine. 57(1). 2493766–2493766. 1 indexed citations
4.
Qiao, Rong, Wenli Li, Runbo Zhong, et al.. (2025). The association between blood-based HYAL2 methylation and early-stage lung cancer: a case-control study. PubMed. 14(1). 2477411–2477411.
5.
Han, Bing, Hua Zhong, Runbo Zhong, et al.. (2024). 1322P A phase II trial of autologous cytokine-induced killer (CIK) therapy plus toripalimab with or without chemotherapy as first-line treatment in advance NSCLC. Annals of Oncology. 35. S841–S841. 1 indexed citations
6.
Liu, Hongyu, Chao Zhou, Tianqing Chu, et al.. (2024). Prognostic role of serum cytokines level in non-small cell lung cancer patients with anti-PD-1 and chemotherapy combined treatment. Frontiers in Immunology. 15. 1430301–1430301. 3 indexed citations
7.
Zheng, Liang, Fang Hu, Lin Huang, et al.. (2024). Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer. Journal for ImmunoTherapy of Cancer. 12(4). e008190–e008190. 6 indexed citations
8.
9.
10.
Xu, Jianlin, Shuyuan Wang, Runbo Zhong, et al.. (2023). On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer. Frontiers in Immunology. 14. 1173025–1173025. 3 indexed citations
11.
Lü, Jun, Yuqing Lou, Yanwei Zhang, et al.. (2023). Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery. International Journal of Nanomedicine. Volume 18. 263–276. 10 indexed citations
12.
13.
Hu, Yaohua, Jianlin Xu, Rong Qiao, et al.. (2023). Multi‐target angiogenesis inhibitor combined with PD‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of EGFR‐TKI therapy. International Journal of Cancer. 153(3). 635–643. 21 indexed citations
14.
Han, Baohui, Tianqing Chu, Runbo Zhong, et al.. (2021). OA07.09 Sintilimab in Combination with Anlotinib as First-Line Therapy for Advanced NSCLC: Final Analysis of Primary Endpoints. Journal of Thoracic Oncology. 16(3). S119–S119.
15.
Xu, Jianlin, Rong Qiao, Yizhuo Zhao, et al.. (2020). Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer. Journal of Oncology. 2020. 1–7. 6 indexed citations
16.
Han, Baohui, Tianqing Chu, X. Zhang, et al.. (2019). P1.01-95 Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology. 14(10). S398–S398. 5 indexed citations
17.
18.
Bai, Hao, et al.. (2016). Real-time PCR assay with high resolution melting for EGFR and BIM mutation of lung cancer.. PubMed. 20(13). 2805–11. 3 indexed citations
19.
Wang, Lei, Weihua Wu, Jiajun Teng, et al.. (2016). Sonographic Features of Endobronchial Ultrasound in Differentiation of Benign Lymph Nodes. Ultrasound in Medicine & Biology. 42(12). 2785–2793. 15 indexed citations
20.
Zhong, Runbo, Jiajun Teng, Baohui Han, & Hua Zhong. (2011). Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunology Immunotherapy. 60(10). 1497–1502. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hari Menon Breakdown of academic impact, for papers by Chuanyong Mu Breakdown of academic impact, for papers by Simon Laban Breakdown of academic impact, for papers by Alexandra S. Zimmer Breakdown of academic impact, for papers by Margaret E. Gatti‐Mays Breakdown of academic impact, for papers by Max M. Wattenberg Breakdown of academic impact, for papers by Gabriele Gamerith Breakdown of academic impact, for papers by An Coosemans Breakdown of academic impact, for papers by Shuhua Wei Breakdown of academic impact, for papers by Carlos de Andrea
Rankless by CCL
2026